Abstract
Thirty-nine dogs with severe and/or recurrent lesions of pyoderma were treated with marbofloxacin at an average dosage of 2.12 mg/kg bodyweight, once daily, for time periods varing from 10 to 213 days. Forty-seven strains of bacteria, isolated from 34 cultures, were tested for sensitivity to various antibiotics. At day 0, no resistance to marbofloxacin was found, but one refractory case, a strain of Staphylococcus intermedius resistant to marbofloxacin, was cultured at day 28. Thirty-three dogs (84.6 per cent) showed an excellent response (cure), one (2.6 per cent) a clear improvement and one (2.6 per cent) a smaller improvement, while the remaining four dogs showed no response after 11 to 60 days. Fifteen dogs (45.5 per cent) relapsed over the follow-up period of three to 191 days, but none of the dogs in the study exhibited any adverse effects.
MeSH terms
-
Animals
-
Anti-Infective Agents / administration & dosage*
-
Body Weight
-
Cellulitis / drug therapy
-
Cellulitis / microbiology
-
Cellulitis / veterinary
-
Dog Diseases / drug therapy*
-
Dogs
-
Enzyme Inhibitors / administration & dosage*
-
Erythema / drug therapy
-
Erythema / microbiology
-
Erythema / veterinary
-
Female
-
Fluoroquinolones*
-
Folliculitis / drug therapy
-
Folliculitis / microbiology
-
Folliculitis / veterinary
-
Follow-Up Studies
-
Male
-
Microbial Sensitivity Tests
-
Pruritus / drug therapy
-
Pruritus / microbiology
-
Pruritus / veterinary
-
Pyoderma / drug therapy*
-
Pyoderma / microbiology
-
Pyoderma / veterinary*
-
Quinolones / administration & dosage*
-
Recurrence
-
Skin Ulcer / drug therapy
-
Skin Ulcer / microbiology
-
Skin Ulcer / veterinary
-
Staphylococcal Infections / drug therapy
-
Treatment Outcome
Substances
-
Anti-Infective Agents
-
Enzyme Inhibitors
-
Fluoroquinolones
-
Quinolones
-
marbofloxacin